Tesamorelin, CJC-1295 (no DAC), Ipamorelin 12mg (Blend) — Advanced Triple-Action Growth Hormone Secretagogue Research Blend

This advanced 12mg synergistic powerhouse combines three of the most prominent growth hormone-releasing peptides in contemporary biochemical research: Tesamorelin, CJC-1295 (no DAC), and Ipamorelin. By combining two distinct Growth Hormone-Releasing Hormone (GHRH) analogues with a highly selective Growth Hormone Secretagogue Receptor (GHSR) agonist, this formulation delivers a multi-pathway architecture designed to investigate maximized, pulsatile endogenous growth hormone amplification.

• Triple-Pathway Synergistic Architecture: Simultaneously targets pituitary GHRH and ghrelin/secretagogue receptors. The dual-GHRH component evaluates complementary binding kinetics to achieve sustained cellular signaling without severely altering normal baseline parameters like cortisol or prolactin.

• Key Research Areas: Extensively utilized in metabolic, endocrinological, and cellular aging studies to investigate visceral adipose tissue reduction, lipid metabolism, muscle-to-fat body composition mechanics, and cellular repair pathways.

• Purity Guaranteed: $\ge 99\%$ purity for each constituent peptide within the blend, verified by stringent HPLC and Mass Spectrometry testing to preserve precise experimental baselines.

• Optimal Stability: Supplied as a sterile, lyophilized powder format to protect structural integrity and allow for precise reconstitution in in vitro and laboratory assays.

Note: This product is sold strictly as a high-purity research chemical. It is intended solely for laboratory, in vitro, or animal research applications and is not approved for human injection, therapeutic, or diagnostic use.